STOCK TITAN

Teva (NYSE: TEVA) accounting chief sells 9,445 shares at up to $37.63

(Moderate)
(Negative)
Form Type
4

Rhea-AI Filing Summary

TEVA (TEVA PHARMACEUTICAL INDUSTRIES LTD) reported insider transactions by Chief Accounting Officer Amir Weiss on 2026-08-21. Weiss exercised stock options covering 2,500 Ordinary Shares at an exercise price of $19.16 per share and then sold a total of 9,445 Ordinary Shares in open-market transactions, including 6,945 shares at a weighted average price of $37.61 (in a range of $31.62 to $37.61) and 2,500 shares at $37.63 per share. The options, which expire on March 2, 2028, were originally granted in 2018 and vested in tranches from 2019 to 2022. The Ordinary Shares may be represented by American Depositary Shares, each currently representing one Ordinary Share.

Positive

  • None.

Negative

  • None.
Insider Weiss Amir
Role Chief Accounting Officer
Sold 9,445 shs ($355K)
Approx. gross sale proceeds $355K
Approx. exercise cost $48K
Type Security Shares Price Value
Exercise Stock Options (right to buy) F3, F1 2,500 $19.16 $48K
Sale Ordinary Shares F1, F2 6,945 $37.6133 $261K
Exercise Ordinary Shares F1 2,500 $19.61 $49K
Sale Ordinary Shares F1 2,500 $37.6307 $94K
Holdings After Transaction: Stock Options (right to buy) — 7,502 shares (Direct); Ordinary Shares — 13,071 shares (Direct)
Footnotes (3)
  1. F1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
  2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.61 to $31.62, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
  3. F3. Stock options were granted on March 3, 2018, with 2,500 having vested on each of March 2, 2019, March 2, 2020 and March 2, 2021 and 2,502 having vested on March 2, 2022.
Options exercised 2,500 Ordinary Shares Stock options (right to buy) exercised on 2026-08-21
Exercise price $19.16 per share Exercise price of stock options for 2,500 Ordinary Shares
Shares sold (block 1) 6,945 Ordinary Shares Sold on 2026-08-21 at weighted average price
Weighted average sale price (block 1) $37.6133 per share Weighted average sale price for 6,945 shares; individual trades from $31.62 to $37.61
Price range (block 1 sales) $31.62–$37.61 per share Range of prices for multiple transactions in the 6,945-share sale block
Shares sold (block 2) 2,500 Ordinary Shares Sold on 2026-08-21 in a separate transaction
Sale price (block 2) $37.6307 per share Sale price for 2,500 Ordinary Shares on 2026-08-21
Options remaining after transaction 7,502 options Total options reported following the option exercise transaction
Stock Options (right to buy financial
"security_title: "Stock Options (right to buy)""
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
American Depositary Shares financial
"The Ordinary Shares may be represented by American Depositary Shares, each of which currently"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
Ordinary Shares financial
"The Ordinary Shares may be represented by American Depositary Shares, each of which currently"
Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.
exercise or conversion of derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""

FAQ

What insider transactions did TEVA (TEVA) report for Amir Weiss on August 21, 2026?

TEVA reported that Chief Accounting Officer Amir Weiss exercised stock options for 2,500 Ordinary Shares at $19.16 per share and sold a total of 9,445 Ordinary Shares in open-market transactions on 2026-08-21.

How many TEVA (TEVA) shares did Amir Weiss sell and at what prices?

Amir Weiss sold 9,445 Ordinary Shares: 6,945 shares at a weighted average price of $37.61 (range $31.62–$37.61) and an additional 2,500 shares at $37.63 per share.

What options did Amir Weiss exercise in TEVA (TEVA) and at what price?

He exercised stock options labeled “Stock Options (right to buy)” for 2,500 Ordinary Shares at an exercise price of $19.16 per share. These options were part of a 2018 grant and expire on March 2, 2028.

Were the TEVA (TEVA) insider sales by Amir Weiss part of a Rule 10b5-1 plan?

No. The filing’s Rule 10b5-1 checkbox is not marked as relying on a trading plan (aff_10b5_one: false), and the footnotes do not state that the transactions were made pursuant to a Rule 10b5-1 plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Weiss Amir

(Last)(First)(Middle)
C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.
124 DVORA HANEVI'A ST.,

(Street)
TEL AVIV6944020

(City)(State)(Zip)

ISRAEL

(Country)
2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Accounting Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/21/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares(1)08/21/2026S6,945D$37.6133(2)13,071D
Ordinary Shares(1)08/21/2026M2,500A$19.6115,571D
Ordinary Shares(1)08/21/2026S2,500D$37.630713,071D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Options (right to buy)$19.1608/21/2026M2,500 (3)03/02/2028Ordinary Shares(1)2,500$19.167,502D
Explanation of Responses:
1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.61 to $31.62, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
3. Stock options were granted on March 3, 2018, with 2,500 having vested on each of March 2, 2019, March 2, 2020 and March 2, 2021 and 2,502 having vested on March 2, 2022.
Dov Bergwerk as attorney-in-fact for Amir Weiss08/25/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)